Expanded Access (“Compassionate Use” or “Early Access”) Statement
Clinical development is a critical part of evaluating experimental drugs as potential impactful medicines for children with rare cholestatic liver diseases. Our ultimate goal is the rigorous testing of the experimental drugs with the aim of securing regulatory approval and enabling the medicine to be available to as many patients as possible as quickly as possible.
If you would like more information on our planned Expanded Access Program for Alagille syndrome (ALGS) patients, in the U.S. and Canada, please visit www.algseap.com.
If you would like more information on our MARCH-PFIC Phase 3 study please visit www.pfictrial.com, or email us at email@example.com.